CAG
AXDX

Csenge Advisory Group’s Accelerate Diagnostics AXDX Stock Holding History

Csenge Advisory Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20
Closed -$2K – 309
2018
Q3 		$2K Buy
+20
New +$4.42K ﹤0.01% 731

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Csenge Advisory Group's AXDX Position: Q4 2018 in Review

Csenge Advisory Group sold out of Accelerate Diagnostics (AXDX) in Q4 2018, closing a stake of 20 shares — an estimated $2K sold.

Csenge Advisory Group first reported a position in AXDX in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2018.

  • Csenge Advisory Group reported no remaining Accelerate Diagnostics position as of Q4 2018 after selling out during the quarter.
  • Csenge Advisory Group sold 20 Accelerate Diagnostics shares in Q4 2018, an estimated $2K.
  • Csenge Advisory Group first reported a position in Accelerate Diagnostics in Q3 2018 and held it in 1 quarter.
  • Csenge Advisory Group's Accelerate Diagnostics position peaked at $2K in Q3 2018.
  • 107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.